Login to Your Account



Guilford Licenses Inhibitor Class To Pfizer As Part Of Broad Deal

By Aaron Lorenzo


Friday, May 9, 2003
Guilford Pharmaceuticals Inc. is licensing an entire class of potential neurodegenerative disease drugs to Pfizer Inc. for $5 million up front in a deal that could become much more lucrative down the road. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription